Skip to main
GRDN
GRDN logo

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Services Inc is leveraging its strong technological capabilities to enhance value-based care discussions, which position it favorably for future growth. The integration of its technology platforms into newly acquired operations is expected to be a significant driver of margins and operational efficiency, contributing to robust earnings potential. Additionally, the company's substantial market share and the efficiency gains from its robotic dispensing systems, which enhance accuracy and reduce requisition fulfillment times, further support a positive outlook for its financial performance.

Bears say

Guardian Pharmacy Services Inc faces several significant risks that contribute to a negative outlook on its stock. Key concerns include potential regulatory and reimbursement changes that may impact revenue stability, challenges in managing relationships with long-term care facilities, and supply chain disruptions that could hinder operational efficiency. Additionally, difficulties in hiring and retaining clinical staff, alongside issues in sourcing and integrating acquisitions, further exacerbate the company's vulnerabilities, especially given its reliance on IT and technology assets.

GRDN has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 2 analysts, GRDN has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.